This document presents a case scenario for choosing the best management strategy for a 73-year-old male patient with hormone-naïve metastatic prostate cancer. The patient has bone metastases, a PSA of 115 ng/ml, and biopsy-confirmed Grade 4 prostate adenocarcinoma. Treatment options discussed include ADT alone, ADT plus abiraterone, ADT plus docetaxel, and newer approvals like apalutamide and enzalutamide. Key trials comparing these options are summarized. Factors to consider in choosing a treatment include availability, tolerability, differential toxicity profiles, and efficacy based on the patient's individual risk profile. For this patient who has completed ADT plus doc